Global Drug Approvals: February 2026 Roundup

Updated on March 20,2026|Written by Patsnap Team

February 2026 saw 19 new drugs receive marketing authorization across five major regulatory jurisdictions — the United States, China, the European Union, South Korea, and Japan. The month’s cohort spanned small molecules, monoclonal antibodies, biosimilars, inactivated vaccines, and two landmark iPSC-derived cell therapies. Oncology and rare disease continued to dominate, while KRAS-targeted agents marked a regional first in China.

All data in this report is sourced from Patsnap Synapse, an AI-powered drug intelligence platform tracking 130,000+ drugs, 16M+ pharmaceutical patents, and 1M+ clinical trials globally.

Approvals by Jurisdiction

South Korea led in volume with 7 approvals, largely driven by combination small molecule products. China’s 6 approvals included two significant oncology firsts. Japan made history with back-to-back iPSC-derived cell therapy approvals — the world’s first of their kind.

Approvals by Drug Modality

• Small molecule drugs — 10 approvals (53%), including a first-in-class KRAS G12C inhibitor
• Monoclonal antibodies / biosimilars — 5 approvals, covering TNF-α, HER2, IL-17A, CD20, and VEGF-A
• iPSC-derived cell therapies — 2 approvals (Japan)
• Vaccines — 2 approvals (inactivated influenza and rabies)
• Synthetic peptide — 1 approval (Navepegritide, US)

Need to filter approvals by target, modality, indication, or region? Explore the Patsnap Synapse drug tracker →

Patsnap Synapse tracks every approval and ERP designation across FDA, NMPA, EMA, and PMDA in real time — connected to patent, clinical trial, and competitive data. Explore regulatory intelligence →

Full Approval Table — February 2026

Key Highlights

Navepegritide (Yuviwel): first once-weekly therapy for achondroplasia

The FDA approved Navepegritide — branded Yuviwel — on February 27 for achondroplasia. It is the first once-weekly treatment in this indication, and the only one providing continuous systemic CNP exposure over the dosing interval. The drug targets NPRC to reduce CNP clearance, amplifying CNP–NPR-B–cGMP signalling at growth plate chondrocytes. Approval was based on three randomized, double-blind, placebo-controlled trials including the pivotal ApproaCH study published in JAMA Pediatrics.

Official source: Ascendis Pharma FDA approval announcement | FDA prescribing information (PDF)

→ Deep dive: Navepegritide — NPRC mechanism, patents, competitive landscape

Sosimerasib: China’s first domestically developed KRAS G12C inhibitor

KRAS G12C inhibition became clinically actionable with the 2021 FDA approval of sotorasib, followed by adagrasib in 2022 — but until February 2026, no domestically developed Chinese agent had crossed the regulatory line. Sosimerasib (Zhejiang Hangyu) fills that gap and also received Conditional Marketing Approval status simultaneously. For clinical context on the class, see this FDA approval summary of sotorasib on PMC and a recent Nature review of KRAS G12C resistance mechanisms.

→ Deep dive: KRAS G12C/G12D — three agents, one month

Japan’s iPSC landmark: two firsts in one month

Japan approved Raguneprocel (Amchepry) for Parkinson’s disease and ReHeart (iPSC-derived cardiomyocytes) for heart failure in the same month — the world’s first commercial approvals of iPSC-derived cell therapies. Both carry conditional, time-limited status (seven years) requiring post-market confirmatory data. The Michael J. Fox Foundation described the raguneprocel approval as “a significant scientific milestone for the Parkinson’s community”. Nature’s news team covered the broader significance in this analysis of Japan’s first-of-a-kind approvals.

→ Deep dive: Japan’s iPSC approvals — what they mean for regenerative medicine

Expedited Review Pathways: February at a Glance

Beyond full approvals, 82 drugs received expedited review designations in February 2026:

Oncology dominated Breakthrough Therapy designations — 7 of 12 grants were cancer-related. Rilzabrutinib (Sanofi) received Breakthrough Therapy designation for warm autoimmune hemolytic anemia, the first BTK inhibitor to achieve this designation for that indication. Full details are in the official Sanofi press release.

→ Full ERP analysis: Expedited review designations, February 2026

What to Watch in March 2026

• Nomlabofusp (FXN fusion protein, Friedreich Ataxia) — Breakthrough Therapy, Larimar Therapeutics
• Rilzabrutinib (BTK inhibitor, warm AIHA) — Breakthrough Therapy, Sanofi; Phase 3 LUMINA 3 trial (NCT07086976) ongoing
• Olezarsen Sodium (APOC3 ASO, hypertriglyceridemia) — Priority Review, Ionis Pharmaceuticals
• Pariglasgene brecaparvovec (AAV gene therapy, Glycogen Storage Disease I) — Priority Review, Ultragenyx

BD teams and portfolio managers use Patsnap Synapse to assess asset value, identify licensing opportunities, and track competitor milestones. See how Synapse supports BD decisions →

Patsnap Synapse tracks every drug approval, ERP designation, and pipeline movement in real time — connected to patent data, clinical trials, and competitive landscapes for 48,000+ targets. Built for researchers, BD teams, and portfolio strategists who need more than a news feed. Start your free trial →

Monthly drug approvals, ERP designations, competitor pipeline shifts — Patsnap Synapse helps drug development and BD teams stay ahead of the curve. Request a demo →

Further Reading

• US & EU drug approvals — February 2026
• APAC drug approvals — China and South Korea, February 2026
• Japan iPSC approvals — February 2026
• Breakthrough Therapy designations — February 2026
• Navepegritide: NPRC target profile and competitive landscape
• Rilzabrutinib: BTK inhibition in warm autoimmune hemolytic anemia

Data sourced from Patsnap Synapse. Approval dates and pathway classifications reflect regulatory filings as of February 2026. This post is for informational purposes only.